Aduro BioTech, Inc. (ADRO) EPS Estimated At $-0.22 as of May, 1

Investors expect Aduro BioTech, Inc. (NASDAQ:ADRO)’s quarterly earnings on May, 1., according to Faxor. Analysts predict 21.43 % diference or $-0.22 from the $-0.28 EPS from 2018. Analysts at Wall Street see Aduro BioTech, Inc.’s -21.43 % EPS growth compared to $-0.28 EPS for last quarter. The stock increased 3.65% or $0.14 during the last trading session, touching $3.98.Currently Aduro BioTech, Inc. is downtrending after 31.87% change in last April 1, 2018. ADRO has 292,982 shares volume. ADRO underperformed by 36.24% the S&P500.

Aduro BioTech, Inc. (NASDAQ:ADRO) Ratings Coverage

A total of 2 analysts rate Aduro Biotech (NASDAQ:ADRO) as follows: 2 “Buy”, 0 “Hold” and 0 “Sell”. Š¢herefore 100% are bullish. (NASDAQ:ADRO) has 4 ratings reports on Apr 1, 2019 according to StockzIntelligence. On Tuesday, November 13 the rating was maintained by Canaccord Genuity with “Buy”. The company rating was maintained by H.C. Wainwright on Thursday, February 28.

Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases.The firm is valued at $317.81 million. It is developing CRS-207, which has completed Phase Ib clinical trials for the treatment of unresectable malignant pleural mesothelioma; that has completed Phase II clinical trials for the treatment of pancreatic cancer; and that is in Phase I/II clinical trials for the treatment of ovarian cancer.Last it reported negative earnings. The firm is also developing ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; ADU-741, which is in Phase I clinical trials for the treatment of prostate cancer; and a product candidate for the treatment of patients with cancers of the gastrointestinal tract.

For more Aduro BioTech, Inc. (NASDAQ:ADRO) news posted recently go to: Nasdaq.com, Benzinga.com, Globenewswire.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Why Is Aduro Biotech (ADRO) Down 10.7% Since Last Earnings Report? – Nasdaq” posted on March 29, 2019, “Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs (March 31-April 6) – Benzinga” on March 30, 2019, “Aduro Biotech Announces Strategic Reset Nasdaq:ADRO – GlobeNewswire” with a publish date: January 30, 2019, “Lilly (LLY) Signs New Immunology Deal With Private Biotech – Nasdaq” and the last “Key events next week – healthcare – Seeking Alpha” with publication date: March 22, 2019.

Aduro BioTech, Inc. (NASDAQ:ADRO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.